Wave Life Sciences (WVE) Net Cash Flow (2014 - 2026)

Wave Life Sciences (WVE) has 13 years of Net Cash Flow data on file, last reported at -$176.7 million in Q2 2026.

• Quarterly Net Cash Flow fell 410.34% year-over-year to -$176.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $159.5 million (up 192.94% YoY) and the FY2025 annual result came in at $300.0 million, up 194.35% from the prior year.
• Net Cash Flow eased to -$176.7 million in Q2 2026, from -$57.5 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $405.9 million in Q4 2025 to a low of -$176.7 million in Q2 2026.
• A 5-year average of $12.1 million and a median of -$22.7 million in 2022 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2025 — Net Cash Flow jumped 4737.5% — and 2026, when it plunged 410.34%.
• Tracing WVE's Net Cash Flow over 5 years: stood at -$8.5 million in 2022, then soared by 806.46% to $60.4 million in 2023, then plunged by 114.5% to -$8.8 million in 2024, then jumped by 4737.5% to $405.9 million in 2025, then slumped by 143.53% to -$176.7 million in 2026.
• The last three Net Cash Flow figures came in at -$176.7 million (Q2 2026), -$57.5 million (Q1 2026), and $405.9 million (Q4 2025), per Business Quant data.